In this article, we discuss the 5 healthcare stocks to buy according to Mario Gabelli. If you want to read our detailed analysis of these stocks, go directly to the 10 Healthcare Stocks to Buy According to Billionaire Mario Gabelli.
At Insider Monkey we leave no stone unturned when looking for the next great investment idea. For example, lithium mining is one of the fastest growing industries right now, so we are checking out stock pitches like this emerging lithium stock. We go through lists like the 10 best hydrogen fuel cell stocks to pick the next Tesla that will deliver a 10x return. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. You can subscribe to our free daily newsletter on our homepage. Let’s now take a look at Gabelli’s healthcare stock picks:
5. Zoetis Inc. (NYSE: ZTS)
Number of Hedge Fund Holders: 58
Zoetis Inc. (NYSE: ZTS) is ranked fifth on our list of 10 healthcare stocks to buy according to Mario Gabelli. The company makes and sells animal medicines and is headquartered in New Jersey. Latest filings reveal that GAMCO Investors owned 105,050 shares in the company at the end of the second quarter of 2021 worth $19 million, representing 0.16% of the portfolio.
On August 25, investment advisory Argus maintained a Buy rating on Zoetis Inc. (NYSE: ZTS) stock and raised the price target to $225 from $195, noting the upgrade reflected the improved outlook on the firm following solid quarterly results posted earlier.
Out of the hedge funds being tracked by Insider Monkey, London-based investment firm Marshall Wace LLP is a leading shareholder in Zoetis Inc. (NYSE: ZTS) with 951,285 shares worth more than $177 million.
In its Q2 2021 investor letter, Polen Capital, an asset management firm, highlighted a few stocks and Zoetis Inc. (NYSE: ZTS) was one of them. Here is what the fund said:
“As is usually the case, Portfolio turnover was modest during the quarter. We trimmed Zoetis. The Zoetis trim is simply an acknowledgement of the company’s current valuation, which we assess is elevated.”
4. Thermo Fisher Scientific Inc. (NYSE: TMO)
Number of Hedge Fund Holders: 87
Thermo Fisher Scientific Inc. (NYSE: TMO) is a Waltham-based firm that markets life sciences and specialty diagnostics services. It is placed fourth on our list of 10 healthcare stocks to buy according to Mario Gabelli. 13F filings show that GAMCO Investors owned 42,870 shares in the company at the end of June 2021 worth $21 million, representing 0.18% of the portfolio.
On August 4, investment advisory Credit Suisse assumed coverage of Thermo Fisher Scientific Inc. (NYSE: TMO) stock with an Outperform rating and a price target of $580. Katie Tryhane, an analyst at the advisory, issued the ratings update.
At the end of the second quarter of 2021, 87 hedge funds in the database of Insider Monkey held stakes worth $7.3 billion in Thermo Fisher Scientific Inc. (NYSE: TMO), up from 79 in the preceding quarter worth $6.2 billion.
In its Q2 2021 investor letter, DEVON Equity Management, an asset management firm, highlighted a few stocks and Thermo Fisher Scientific Inc. (NYSE: TMO) was one of them. Here is what the fund said:
“The broad response to the COVID pandemic from the healthcare, pharmaceutical, and life science industries has been nothing short of incredible.
Whilst Vaccine makers understandably garner the highest profile, Thermo Fisher (6.2% of NAV) should be considered one of the outstanding performers, reflected in their ‘COVID related revenue’ hitting US$9.4bn in the 12 months since March 2020 (we appreciate measuring ‘contribution’ to the pandemic by ‘dollars’ generated is a little crude – but ultimately it does tell us something).
Ever the short-termist, Mr Market has looked to the inevitable slowdown in COVID related revenue uneasily – questioning whether it might mean a decline in Earnings come 2022. These concerns resulted in TMO shares declining 5% since their November 2020 peak, the worst performer of our Top 10 holdings.
Fortunately, we look at the COVID dynamic for Thermo in the diametrically opposite fashion.
We think Thermo’s response to COVID has bolstered their competitive positon in multiple verticals, and meaningfully enhanced the long term earnings potential of the company:
Firstly, Thermo came from ‘also-ran’ to leading player in diagnostic testing in 6 months. In ordinary times, this might be expected to take 5+ years. As demand for COVID testing inevitably declines, the capacity Thermo built during 2020 will be filled with demand from non-COVID diagnostic tests, a fast growing area before the pandemic with improved prospects in light of the role testing is playing in the COVID response.
Secondly, Thermo invested heavily throughout 2020 in capacity for the core bioreactor business. Given our constructive view on biologics manufacturing (both volume and value), these investments should translate into sustainably higher market share.
Thirdly, we expect the ~US$4bn of ‘excess’ free cash flow generated from COVID related business to be reinvested into high returning businesses with a more sustainable earnings profile. This is already evident in Thermo’s strong M&A activity YTD, culminating in the US$20bn acquisition of PPD (PPD US).
PPD is a top tier CRO (Contract Research Organisation) which has been in and out of private equity ownership in recent times. To oversimplify, CRO’s effectively provide ‘outsourced’ R&D services across the entire customer spectrum (from big pharma to early stage biotech). Their value proposition varies slightly be customer, but ultimately comes down to quality of drug discovery / development and accelerating time to market (i.e. ‘Return on R&D investment’). CROs must stack up well on this metric vs in-house R&D spend, otherwise Firms would simply keep the spend 100% internal.
In the past Marc Casper (Thermo’s CEO) has been publically sceptical of moving into the CRO market – the simple logic being the creation of an integrated CRO/CDMO6 would bring Thermo into more direct competition with some of their large customers. However the acceleration in R&D spending from big pharma and explosion of innovative R&D activity in well-funded earlier stage Biotechs has driven a boom in the CRO market. COVID and the therapeutic / vaccine responses has added a further leg to the story, and the value proposition of top tier CRO’s has never been stronger.
From a regulatory perspective, one might also point to the relative ease for Thermo to execute a US$20bn CRO acquisition given this is essentially a ‘vertical’ rather than ‘horizontal’ move. Since Thermo are Top 3 in the majority of their segments, any further consolidation of direct competitors in an existing business of comparable size to PPD could prove problematic. Though PPD is ‘vertical’ – we can clearly see synergies with Thermo’s existing businesses, especially in CDMO and clinical trial drug provision / services. The targeted synergies announced in April feel highly conservative, and combined with the obvious potential for accelerated top line performance at PPD once in the Thermo stable, we expect the deal to prove far more accretive on a 3-5 year view than the ~8% earnings accretion based on publicly stated 2022 targets.
Thermo Fisher (and Danaher) have built highly successful multi-brand life science conglomerates, with M&A a critical driver of success. Our confidence in Thermo’s management team to reinvest a large portion of free cash flow into M&A at high rates of return is a key facet of our investment thesis. Done well, inorganic growth can be disproportionately accretive since consensus expectations rarely capture acquisitions as a source of future earnings (even in a demonstrably acquisitive business model such as this).
We established Thermo as a Top 5 position at the Fund’s inception to reflect the company’s strong positioning across a number of attractive life science verticals, with Biopharma and Clinical representing ~70% of end market exposure. We are also attracted to a business model delivering strong and consistent free cash flow generation underpinned by over 50% of revenue derived from consumables.
Given the Fund’s largest position (IQVIA) is a major competitor to PPD, it should come as no surprise we are excited at the prospect of Thermo’s move into the CRO market – in our view one of the most attractive areas of healthcare. Thinking about possible implications for IQVIA, we are not overly concerned about market share loss over the medium term. The CRO market remains fragmented, and we think IQVIA (standalone) and PPD (under Thermo ownership) represent two of the top tier players who are likely to gain market share from second and third tier players.
Thermo Fisher trades on 22x Forward Earnings with a Free Cash Flow Yield in excess of 4%: cheap vs its own history, closest comp Danaher, and the broader life science tools sector. We are comfortable with the possibility of a modest earnings decline in 2022 – to us it would be a reflection of the extent of their successful response to COVID. Recent developments give us increased confidence in the five year earnings and free cash flow prospects for the company. “
3. CVS Health Corporation (NYSE: CVS)
Number of Hedge Fund Holders: 67
CVS Health Corporation (NYSE: CVS) is a Rhode Island-based company that provides healthcare services. It is ranked third on our list of 10 healthcare stocks to buy according to Mario Gabelli. Securities filings show that GAMCO Investors owned 267,131 shares in the company at the end of the second quarter of 2021 worth $22 million, representing 0.18% of the portfolio.
On August 31, investment advisory CVS Health Corporation kept an Overweight rating on CVS Health Corporation (NYSE: CVS) stock and raised the price target to $114 from $99, noting that the firm was a top pick for the rest of the year.
Out of the hedge funds being tracked by Insider Monkey, Chicago-based firm Harris Associates is a leading shareholder in CVS Health Corporation (NYSE: CVS) with 8.5 million shares worth more than $713 million.
In its Q1 2021 investor letter, Vulcan Value Partners, an asset management firm, highlighted a few stocks and CVS Health Corporation (NYSE: CVS) was one of them. Here is what the fund said:
“We sold our position in CVS Health Corp. to allocate capital to companies with larger margins of safety. During the five years that we owned CVS Health Corp., the company acquired Aetna. At the time, we also owned Aetna, and we believed the combination of the two companies would create additional value. After the acquisition, its business performance has been disappointing. We reevaluated our assumptions and determined its value has not grown.”
2. Bausch Health Companies Inc. (NYSE: BHC)
Number of Hedge Fund Holders: 45
Bausch Health Companies Inc. (NYSE: BHC) is placed second on our list of 10 healthcare stocks to buy according to Mario Gabelli. The company markets pharmaceutical products and is headquartered in Canada. According to the latest data, GAMCO Investors owned 815,133 shares in the company at the end of June 2021 worth $23 million, representing 0.20% of the portfolio.
On August 4, investment advisory Barclays kept an Overweight rating on Bausch Health Companies Inc. (NYSE: BHC) stock but lowered the price target to $31 from $35. Balaji Prasad, an analyst at the firm, issued the ratings update.
At the end of the second quarter of 2021, 45 hedge funds in the database of Insider Monkey held stakes worth $3.9 billion in Bausch Health Companies Inc. (NYSE: BHC), up from 42 in the preceding quarter worth $4 billion.
In its Q1 2021 investor letter, Miller Value Partners, an asset management firm, highlighted a few stocks and Bausch Health Companies Inc. (NYSE: BHC) was one of them. Here is what the fund said:
“Bausch Health Companies (BHC) climbed 55% during the period. Glenview (6% owner) sent a letter to the company in early February arguing the company has not acted to unlock shareholder value and urging the company to sell its eye care business. Shortly after, activist investor Carl Icahn disclosing a 7.83% stake in the company. The company responded to the filing saying that they remain committed to splitting the business into two parts, but are open to pursuing all opportunities. The company reported strong 4Q results with better-than-expected 2021 guidance. 4Q revenue came in at $2,213M slightly ahead of consensus of $2,165M and EPS of $1.34 beat consensus of $1.12. The company guided for 2021 revenue of $8.6-8.8B coming in ahead of expectations of $8.55B with EBITDA of $3.4-3.55B ahead of $3.46B estimated. The company announced the transition of Paul Herendeen to an advisory role to be succeeded by Sam Eldessouky, previously senior vice president, controller and chief accounting officer. Finally, the company announced the sale of Amoun Pharmaceutical for $740M, which was relatively in line with estimates and should help support debt reduction targets ahead of the planned spin-off of Bausch + Lomb eye care business.”
1. Teladoc Health, Inc. (NYSE: TDOC)
Number of Hedge Fund Holders: 43
Teladoc Health, Inc. (NYSE: TDOC) is ranked first on our list of 10 healthcare stocks to buy according to Mario Gabelli. The company markets virtual healthcare services and is headquartered in New York. According to the latest filings, GAMCO Investors owned 162,400 shares in the company at the end of the second quarter of 2021 worth $27 million, representing 0.22% of the portfolio.
On August 9. Investment advisory Cowen maintained an Outperform rating on Teladoc Health, Inc. (NYSE: TDOC) stock but lowered the price target to $188 from $240, noting that there were limited near-term catalysts for the shares.
At the end of the second quarter of 2021, 43 hedge funds in the database of Insider Monkey held stakes worth $3.5 billion in Teladoc Health, Inc. (NYSE: TDOC), up from 42 in the previous quarter worth $3.3 billion.
In its Q4 2020 investor letter, Carillon Tower Advisers, an asset management firm, highlighted a few stocks and Teladoc Health, Inc. (NYSE: TDOC) was one of them. Here is what the fund said:
“Teladoc Health offers remote physician access to patients at home. After experiencing incredible levels of growth throughout the early stages of the pandemic as its unique value proposition rose to the forefront of the healthcare industry, the firm’s shares cooled off a bit as optimistic vaccine data slightly curtailed investor expectations for the firm’s future growth potential. We sold the stock.”
You can also take a peek at 10 Companies that Benefit From Crypto Mining and 10 Best Nickel Stocks to Buy Now.
